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In September 1992, the U.S. Public Health Service (USPHS)
recommended that all women capable of becoming pregnant
should consume 400 µg of folic acid/day on an ongoing basis
to reduce their risk for having a pregnancy affected by spina
bifida and anencephaly (i.e., neural tube defects [NTDs]) (1).
The recommendation was preceded a year earlier by a CDC
recommendation for women at high risk (i.e., those women
who have had an earlier pregnancy affected by an NTD). The
1991 CDC recommendation stated that women at high risk
should plan subsequent pregnancies and consume 4,000
µg/day of folic acid from the time they begin trying to
become pregnant through the first trimester of pregnancy to
reduce their risk (2). The 1992 USPHS recommendation speci-
fied that women at high risk should follow the general popu-
lation recommendation for consumption of 400 µg/day when
not trying to become pregnant (1).
Both of these recommendations were based on scientific
evidence that increased folic acid consumption reduced the
risk for having a pregnancy affected by an NTD. In 1983, a
nonrandomized but controlled trial that studied multivita-
mins containing folic acid determined that folic acid might
prevent NTDs (3). In 1991, the British Medical Research
Council (MRC)-sponsored randomized controlled trial indi-
cated that folic acid alone could reduce the risk for NTD-
affected pregnancies among women who had had an earlier
NTD-affected pregnancy (4). In 1992, a randomized con-
trolled trial in Hungary reported the protective effect of folic
acid-containing multivitamins against first occurrences of
NTDs (5). These two controlled and randomized studies,
together with consistent results from multiple observational
studies, prompted the 1992 USPHS recommendation.
The 1992 USPHS recommendation stated that increased
folic acid consumption could be achieved in three ways: by
increasing consumption of foods rich in naturally occurring
folates, by increasing use of folic acid-containing dietary
supplements, and by fortification of a staple foodstuff (e.g.,
flour). In 1998, a report from the Food and Nutrition Board
of the Institute of Medicine (IOM) stated that women of
reproductive age should consume 400 µg/day of folic acid from
dietary supplements or from fortified foods, in addition to
eating a healthy diet containing natural folate compounds (6).
Since 1992, efforts have been made to increase daily use of
dietary supplements containing 400 µg of folic acid by women
of reproductive age. Additionally, in 1998, the Food and Drug
Administration began requiring the fortification of enriched
cereal grain products with folic acid at the level of 140 µg/100
grams of grain (fortification was optional during March 1996–
December 1997). This level of fortification was chosen to
assist women of reproductive age in increasing their folic acid
consumption by an average of 100 µg of folic acid daily.
This issue of the MMWR Recommendations and Reports
presents data to assess the impact of efforts to prevent NTDs
through increased folic acid consumption. Blood folate levels
for U.S. women of reproductive age from the National Health
and Nutrition Examination Survey (NHANES) for the com-
bined years of 1999 and 2000 were substantially higher than
those determined for the NHANES III samples collected dur-
ing 1988–1994 (7). Because substantial increases have not
occurred in the reported use of folic acid-containing dietary
supplements during 1995–2002 (8), the assumption is that
the majority of this rise in blood folate levels is the result of
consumption of fortified cereal grain products (e.g., bread and
pasta) and from fortified ready-to-eat breakfast cereals. In
addition to an increased availability of folic acid derived from
fortified flour, a substantial number of ready-to-eat cereals have
had increases in their folic acid content (CDC, unpublished
data, 2002). Certain subgroups of the population have expe-
rienced more limited increases in blood folate levels than has
the general population of reproductive-age women. One group
of women attending family planning clinics in Georgia had a
median serum folate level of 8.9 ng/mL, compared with the
NHANES 1999–2000 median of 13.0 ng/mL (9). The rea-
sons for this difference are unknown but could include a lower
level of folic acid consumption among subgroups of the U.S.
population. If so, such subgroups could possibly benefit from
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targeted interventions to promote increased folic acid con-
sumption from breakfast cereals and dietary supplements. In
China, an intensive campaign to encourage use of folic acid
supplements among women planning to start a pregnancy was
highly successful in reducing NTDs among the population (10).
NTD rates have declined by approximately 20%–30% since
the institution of folic acid-fortified cereal grains (11–13). This
decrease is expected on the basis of predicted increases in folic
acid consumption from fortified cereal grains (100 µg/day)
(14). In contrast, the decrease in NTD rates is not the
50%–70% decrease predicted by USPHS in 1992 (1), if all
women of reproductive age were to consume 400 µg of folic
acid/day. The decrease is also lower than what could be
predicted on the basis of the substantial rise in blood folate
levels among U.S. women of reproductive age. Spina bifida
rates in North Carolina appear to have decreased less among
disadvantaged segments of the population (12). Possibly,
women who are most at risk for having NTD-affected
pregnancies do not consume as much fortified food products;
they do not have the same level of access to other sources of
folic acid and could benefit from targeted interventions; or
they do not absorb as much folic acid as do women who are at
lower risk.
In 1995, approximately 52% of reproductive-age women
were aware of the term folic acid, and this increased to 80% in
2002 (8). However, just 20% of women participating in a
2002 March of Dimes survey knew that folic acid could pre-
vent certain birth defects, and the proportion who stated that
they took a vitamin supplement containing folic acid daily
increased from 25% in 1995 to only 31% in 2002 (8). These
findings indicate that educational efforts directed at women
of reproductive age might have had an impact on knowledge
and to a lesser extent on behavior. According to polls taken by
multiple groups, including the March of Dimes (8), women
of reproductive age state that the recommendation of a physi-
cian or other health-care provider would positively influence
their decision to take folic acid-containing dietary supplements.
However, only a minority of women who are currently using a
supplement identify their physician as a source of informa-
tion. A study in Florida (CDC, unpublished data, 2002)
reported that approximately 90% of physicians who responded
to a survey knew that folic acid can prevent NTDs but that a
more limited proportion could identify the recommended daily
dose of 400 µg for the general population; furthermore, an
even more limited proportion could state the recommended
dose of 4,000 µg for women at high risk. This indicates a need
for more educational efforts directed at physicians and other
health-care providers.
Among women who are at high risk for an NTD-affected
pregnancy because they have had an NTD-affected pregnancy
or have spina bifida themselves, approximately 33% reported
regular use of a supplement, and only 48% indicated that they
believed that folic acid is effective in reducing the risk for an
NTD (CDC, unpublished data, 2002). A Texas case-control
study reports that 56% of women who have had an infant
with an NTD recall receiving postpartum advice to use folic
acid, compared with 26% of mothers in the control group.
Women who received advice were more likely to use supplements
regularly than women who did not (41% versus 22%) (15).
These reports reflect the encouraging progress made to
increase folic acid consumption by women of reproductive
age and reduce the proportion of babies born with NTDs.
However, more work needs to be done to reach the goal of
preventing all NTDs that could be avoided if all women who
become pregnant were to follow the 1992 USPHS recommen-
dation. In addition to the work that needs to be done to pre-
vent NTDs, as discussed in the articles in this report, the
policies related to folic acid consumption need to be reviewed
and evaluated, and more research is required to improve un-
derstanding regarding the causes of NTDs. The Food and Drug
Administration mandate to fortify flour and other cereal grain
products has had a positive impact on the folate status of the
U.S. population. Nevertheless, more birth defect prevention
could possibly be achieved by a higher level of grain fortifica-
tion or by fortification of additional types of foods. Physi-
cians and scientists need a better understanding of what
proportion of NTD cases that now occur result from inad-
equate folic acid consumption and what proportion result from
causes unrelated to folic acid. Thus, more research is needed
to better understand the biological mechanism by which folic
acid prevents NTDs and the causes of those cases that are not
connected with folic acid consumption.
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Summary
Since 1998, serum folate levels have increased nationally after mandatory fortification of cereal grain products with folic acid.
Whether serum folate levels have increased among all women has not been well-studied. Identifying characteristics of women with
lower serum folate levels would also be helpful in designing educational campaigns. Data for this report were collected during
January 2000–January 2001. During 2000, blood samples were collected from 1,059 women aged 18–45 years who attended six
family planning clinics in Georgia and analyzed for serum folate levels. This sample included women aged 18–25 years (60%),
black women (41%), and women who had a high school education or less (49%). The median serum folate level (8.9 ng/mL)
among this population was lower than the median of women of childbearing age (13.0 ng/mL) who participated in the 1999–
2000 National Health and Nutrition Examination Survey (NHANES). In logistic regression analysis, women who were black
(odds ratio [OR] = 2.4; 95% confidence interval [CI] = 1.48, 3.96), who smoked (OR = 2.1; 95% CI = 1.26, 3.43), or who
used Depo-Provera® contraceptive injection (manufactured by Pharmacia Corporation, Peapack, New Jersey) (OR = 2.3; 95%
CI = 1.15, 4.62) were more likely to be ranked in the lowest quartile (<6.2 ng/mL) of serum folate concentrations when compared
with the highest quartile (>12.4 ng/mL). Women who consumed cereal regularly (OR = 0.4; 95% CI = 0.26, 0.62) or folic acid
supplements (OR = 0.2; 95% CI = 0.09, 0.30) were the least likely to be in the lowest serum folate quartile. This study indicates
that certain women are at greater risk for having lower serum folate levels, including women who are black, smokers, Depo-
Provera users, and those less likely to eat cereal regularly or to take folic acid supplements. In Georgia, these data are useful in
defining target populations (e.g., black women and smokers) for folic acid education campaigns because public health officials can
develop contextually appropriate messages and outreach approaches for targeting women for folic acid interventions. Ongoing
surveillance of serum folate status among women can guide future intervention efforts.
Introduction
Neural tube defects (NTDs), which are serious birth de-
fects of the brain and spinal cord, affect approximately 4,000
pregnancies each year in the United States (1). Epidemiologic
studies demonstrate that folic acid, when taken in adequate
amounts periconceptionally, can prevent 50%–70% of NTDs
(2). During 1992, the U.S. Public Health Service (USPHS)
recommended that all women of childbearing age take 400 µg
of folic acid to help prevent neural tube defects (2). During
1996, as a way to increase consumption of folic acid among
women of childbearing age, the Food and Drug Administra-
tion mandated that, effective January 1998, synthetic folic acid
be added to enriched cereal grain products (3). Reports from
the 1999 National Health and Nutrition Examination Survey
(NHANES) demonstrates that serum folate levels among child-
bearing age women have increased after fortification. Median
serum folate levels increased from 5.2 ng/mL in NHANES
III (1991–1994) to 13.0 ng/mL in NHANES 1999–2000 for
women aged 15–44 years (4). Whether serum folate levels have
risen equally among all women is not yet known. Certain
women might still be at an increased risk for having a preg-
nancy affected by an NTD as a result of inadequate folic acid
intake.
Serum folate data from subpopulations of women seeking
routine clinical services would be helpful in assessing whether
inadequacies exist. In addition, identifying characteristics
associated with women who have low serum folate levels would
help in designing educational interventions targeted at those
with greatest need for higher folic acid consumption. In this
study, we report serum folate levels of women before their
participation in a folic acid intervention evaluation study in
Georgia family planning clinics during 2000. Only limited
studies postfortification have examined serum folate levels
among populations in the United States (5,6). This study
attempts to identify a group of women at high risk for low
folic acid intake.
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Methods
Data Collection
Data were collected from a separate study designed to evalu-
ate the effectiveness of a folic acid intervention in family plan-
ning clinics in Georgia. During spring 1999, a total of 163
surveys were mailed to county nurses and health directors in
Georgia. Of 118 clinics responding to the survey, 63 clinics
were interested in participating in the evaluation. Of these 63
clinics, six had the necessary staff, laboratory resources, and
patient volume needed for inclusion as a study site. The six
family planning clinics participated in the evaluation during a
12-month period that began in January 2000. The folic acid
intervention was developed by the Georgia Family Planning
Health Program, which provides family planning and health
services to approximately 167,000 female clients annually. The
majority of the women served by the Georgia Family Plan-
ning Program have low-paying jobs or are unemployed (i.e.,
>150% of the federal poverty level), and many are uninsured
(7). The folic acid evaluation measured consumption of
cereal, folic acid supplements, or multivitamins before and
after folic acid education during the study period (January
2000–January 2001). Of women aged 18–45 years who vis-
ited these clinics, 1,059 (60.2%) participated in the study.
Informed consent was obtained in accordance with CDC’s
Institutional Review Board guidelines. Participants provided
venous blood samples and completed a self-administered ques-
tionnaire that collected demographic information, health-
related habits, knowledge regarding folic acid, and folic acid
consumption. Only data obtained from participants’ first vis-
its (i.e., preintervention) were used in this analysis. Blood
samples were analyzed for serum folate by using the Bio-Rad
Quantaphase® II simultaneous folate/vitamin B12 radioassay
(Bio-Rad Laboratories, Hercules, California) by the same CDC
laboratory that analyzed the NHANES samples (4). The blood
assay results were linked to data from the questionnaire.
Analysis
Variables used in the analysis included age, race, educational
level, smoking, and folic acid supplement or multivitamin
intake within the previous 2 days of the visit, number of serv-
ings of breakfast cereal eaten within 2 days of the visit, preg-
nancy intention, marital status, and contraception method.
Folic acid intake within the past 2 days was selected because
recent folic acid use substantially affects blood concentration
of the vitamin (8) and because we believed this to be a more
conservative measure of reported use. Only 24 (2%) women
reported being of Hispanic, Latino, or Spanish origin, and
they were excluded from multivariate analyses because their
numbers were too limited to provide reliable or stable
estimates. Another 2% of the sample included women who
reported being American Indian, Asian, Pacific Islander, or
other, and they were excluded from the multivariate analysis
also because their numbers were too limited to provide reli-
able estimates. The remainder of the sample included women
who reported being black or white.
The question used to assess folic acid intake was, “In the
last 2 days, did you take a folic acid pill or multivitamin?” We
used multivariate logistic regression to compare women in the
lowest serum folate quartiles (<6.2 ng/mL) with women in
the highest serum folate quartile (>12.4 ng/mL).
Results
The median serum folate level for the 1,059 study partici-
pants who attended family planning clinics was 8.9 ng/mL
(range: 1.6–164.0 ng/mL) for the overall sample. Women who
reported using a folic acid pill or multivitamin during the pre-
vious 2 days had a median level of 12.3 ng/mL (range: 3.4–
164.0 ng/mL), and women who reported no use during the
previous 2 days had a median serum folate level of 8.3 ng/mL
(range: 1.6–34.1 ng/mL) (Figure). The serum folate distribu-
tion from a nationally representative sample, NHANES 1999–
2000, has a median of 13.0 ng/mL, a value that is similar to
the median for the women in the Georgia sample who
reported either taking a folic acid supplement or a multivita-
min during the 2 days preceding the visit (Figure).
FIGURE. Serum folate levels from women aged 18–45 years
attending family planning clinics in Georgia (GA) in 2000,
compared with folate levels of women aged 15–44 years in
the National Health and Nutrition Examination Surveys
(NHANES) in 1999–2000
* Reported folic acid supplement or multivitamin use in the previous two days.
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TABLE 1. Sociodemographic and behavioral characteristics
of women attending family planning clinics — Georgia, 2000
Variable Number %
Race/ethnicity
White 586 56.4
Hispanic 24 2.3
Black 429 41.3
Age (yrs)
18–25 629 59.7
26–35 296 28.1
36–45 129 12.2
Education
Eighth grade or less 16 1.5
Some high school 137 13.0
High school graduate or GED 361 34.2
Some college or trade school 437 41.4
College graduate 105 9.9
Marital status
Married 236 22.3
Not married 820 77.7
Birth control method
Birth control pill 421 42.4
Depo-Provera®* 237 23.8
Barrier/withdraw 120 12.1
Other 63 6.3
None 153 14.4
Smoking status
Any cigarettes smoked/day 348 33.2
None 701 66.8
Folic acid use
Used during previous 2 days 175 17.1
None 848 82.9
Cereal consumption
Any bowls eaten during previous 2 days 412 39.2
None eaten 639 60.8
Total† 1,059 —
* Contraceptive injection (manufactured by Pharmacia Corporation,
Peapack, New Jersey).† Numbers might not total 1,059 because of missing data.
Women in this sample were primarily aged 18–25 years
(60%); 41% were black; 42% used oral contraceptives; 33%
were smokers; and the majority were not married (Table 1). In
the adjusted logistic regression model, women who had
serum folate levels in the lowest quartile were more likely to
be black, use Depo-Provera® contraceptive injection (manu-
factured by Pharmacia Corporation, Peapack, New Jersey),
smoke, and report not eating breakfast cereal or using a folic
acid pill or multivitamin during the 2 days preceding the visit
(Table 2).
Discussion
When compared with serum folate levels in a nationally rep-
resentative sample (NHANES 1999–2000), the median in this
sample of women attending Georgia family planning clinics
during 2000 was substantially lower (4). These findings are
also inconsistent with findings of improved folate status among
other subsets of the U.S. population postfortification (5,6).
The population of Georgia women in this study differs from
the 1999 NHANES population (representative of the U.S.
population) by certain characteristics that could explain the
lower serum folate levels. For example, the women who par-
ticipated in the Georgia family planning clinics were more
likely to be young, black, and unmarried compared with other
U.S. women aged 18–45 years. Possibly, these women differ
in their nutritional practices, which could result in differences
in serum folate levels when compared with a national sample.
During 2000, approximately 34% of women aged 18–45
years reported taking folic acid daily (9). In this sample, only
17% reported taking folic acid during the previous 2 days.
The 2000 Gallup poll sample included 21% women aged
18–24 years and only 11% black women (9). In contrast, this
sample had a greater proportion of women who were aged
18–25 years (60%) and black (56%). In addition, only 6% of
family planning clinic patients reported, “planning to get preg-
nant in the next few months or next year.” Folic acid con-
sumption might be viewed by these women as a behavior
associated with pregnancy planning. Because the majority of
the women in our sample were not planning pregnancies, they
might not have been immediately receptive to the folic acid
message and, therefore, might have been less likely to cur-
rently take folic acid. Moreover, benefits of the intervention
could be delayed until women begin to think about pregnancy.
Multivariate analysis demonstrated that women who smoked
or used Depo-Provera were twice as likely to be ranked in the
lowest quartile of serum folate concentrations than in the high-
est quartile. Previous research has indicated that smokers have
substantially lower serum folate levels than nonsmokers (9,10).
However, reports of the association between oral contracep-
tives and serum folate levels are inconsistent (11,12), and no
study has examined the effects of injectable hormones (e.g.,
Depo-Provera) on serum folate levels. No substantial differ-
ence in serum folate status was identified for women taking
oral contraceptives. The findings regarding smoking and con-
traceptive use might be a reflection of inherent differences
among these women (e.g., differences in their metabolic char-
acteristics) as well as related to their behavior.
This analysis also demonstrates that folic acid use, through
a folic acid supplement/multivitamin or breakfast cereal, is
associated with higher serum folate levels and is an effective
method for raising serum folate levels. Misclassification of folic
acid consumption could have occurred because asking about
folic acid consumption during the previous 2 days could have
excluded those women who did not consume folic acid dur-
ing the previous 2 days but were usually habitual consumers.
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TABLE 2. Adjusted* odds ratio for being in the lowest serum folate quartile (<6.2 ng/mL), compared with the highest quartile
(>12.4 ng/mL) among family planning clinic clients — Georgia, 2000
Lowest 25% (n = 277) Highest 25% (n = 264) Odds 95% confidence
Variable Number % Number % ratio interval
Race
Black 120 44.1 86 33.1 2.4 1.48, 3.96
White 144 52.9 165 63.5 Ref —
Age
18–25 168 61.1 148 56.3 1.1 0.58, 2.15
26–35 74 26.9 71 27.0 1.0 0.51, 2.04
36–45 33 12.0 44 12.0 Ref —
Education
Less than high school 54 19.6 34 12.9 1.8 0.98, 3.37
High School or more 221 80.4 230 87.1 Ref —
Marital status
Married 64 23.2 63 23.9 1.4 0.85, 2.40
Not married 212 76.8 201 76.1 Ref —
Contraception method
Birth control pill 88 33.7 124 50.4 0.9 0.51, 1.74
Depo-Provera®† 83 31.8 37 15.0 2.3 1.15, 4.62
Barrier/withdrawal 31 11.9 30 12.2 1.1 0.48, 2.29
Other 19 7.3 21 8.5 0.7 0.28, 1.75
None 40 15.3 34 13.8 Ref —
Smoking status
Any 103 37.5 71 27.0 2.1 1.26, 3.43
None 172 62.6 192 73.0 Ref —
Multivitamin or folic acid pill use
Used during last 2 days 23 8.52 85 33.6 0.2 0.09, 0.30
Did not use during last 2 days 247 91.5 168 66.4 Ref —
Cereal consumption
Any 80 29.2 135 51.5 0.4 0.26, 0.62
None 194 70.8 127 48.5 Ref —
* All variables are adjusted for in a single multivariate logistic regression model.†Contraceptive injection (manufactured by Pharmacia Corporation, Peapack, New Jersey).
However, when controlling for habitual use, defined as taking
a multivitamin >4 times during the previous week, similar
estimates resulted.
This study is subject to certain limitations. It was designed
as part of a folic acid intervention evaluation study and, there-
fore, questions concerning other behavioral characteristics of
the participants were limited. We were unable to collect any
information regarding the women’s dietary habits other than
cereal consumption, which could explain differences in serum
folate levels among this group. Other limitations include the
low participation rate (60%). Requesting samples of blood
might have been a deterrent to participation. The limited
sample size limits the conclusions that can be drawn from this
study. Further research is needed to determine the reason for
these associations between serum folate levels and race, smok-
ing, and injectable contraceptives. Serum folate is a valid mea-
sure of folate consumption, but it might not be directly
predictive of the risk for NTDs. One strength of the study
includes the use of CDC’s laboratory that processed both the
NHANES 1999 and Georgia blood assays. Using the same
laboratory reduced the number of errors resulting from vari-
ances in laboratory techniques.
Although serum folate levels have increased in the aggregate
national population, certain populations have lower folate lev-
els. Because contraceptive methods are not 100% effective, all
women capable of becoming pregnant, regardless of pregnancy
intention or current birth control use, should consume
adequate amounts of folic acid for preventing NTDs in their
children. Targeting specific populations (e.g., women attend-
ing family planning clinics) who might be at higher risk for
NTDs because of lower folic acid levels can be an effective
strategy for continuing to reduce NTDs in the United States.
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Summary
Spina bifida and anencephaly are serious birth defects. To reduce the occurrence of these birth defects, the Food and Drug
Administration authorized the fortification of all enriched cereal grain products with folic acid in March 1996, with compliance
mandatory by January 1998. This report reviews data reported to CDC’s National Center for Health Statistics (NCHS) regard-
ing spina bifida and anencephaly prevalence for live births in the United States during 1991–2001. Since 1989, NCHS has
compiled birth defect data from checkboxes that appear on birth certificates. For consistency in trends, this report uses data for
1991–2001 from all U.S. reporting areas except Maryland, New Mexico, and New York. Data for 2001 are preliminary.
During1996–2001, a 23% decline occurred in neural tube defects (spina bifida and anencephaly combined). Spina bifida
declined 24% during this period, and anencephaly declined 21%. The United States has experienced declines in spina bifida and
anencephaly cases since folic acid fortification of all enriched cereal grain products. The observed declines have translated into
approximately 920 infants being born without these serious defects each year. Continued monitoring of the occurrence of spina
bifida and anencephaly will be necessary to evaluate the effectiveness of folic acid fortification.
Introduction
In 1992, the U.S. Public Health Service recommended that
women of childbearing age increase consumption of the vita-
min folic acid to reduce the number of spina bifida and anen-
cephaly cases in the United States (1). By 1998, <30% of
women were following this recommendation (2). In 1996, the
Food and Drug Administration (FDA) mandated that all
enriched cereal grain products be fortified with folic acid (3).
An optional period for folic acid cereal grain enrichment started
in March 1996, and mandatory fortification began in January
1998. The National Health and Nutrition Examination Sur-
vey (NHANES) documented that these public health actions
were effective in increasing folate status among U.S. women
of childbearing age from NHANES III (1989–1994) to
NHANES 1999 (4). In 2001, researchers from CDC deter-
mined that the overall birth prevalence of these two neural
tube defects declined 19% after mandatory folic acid fortifi-
cation (5).
Since 1989, birth certificates in the United States have
included 21 checkboxes for birth defects, including spina bifida
and anencephaly, and these data are collected by the National
Vital Statistics System, a component of CDC’s National Center
for Health Statistics (NCHS). This system has been a useful
data source to determine the effect of folic acid fortification
and other sources of folic acid supplementation (5).
Methods
NCHS receives birth certificate data collected by state vital
statistics offices for the approximately four million births
occurring in the United States annually. Data for Maryland,
New Mexico, and New York, which had incomplete reporting
or did not require reporting for spina bifida and anencephaly
for part of the observation period, were excluded from this
analysis. This analysis includes trends during 1991–2001 in
frequency and prevalence for spina bifida and anencephaly.
Included with the birth prevalence are 95% confidence inter-
vals (CI) to determine statistical significance in changes over
time. Data for 1991–2000 are final but are preliminary for
2001. The 2001 preliminary data are based on >96% of all
births in 2001. More detailed explanations of final and pre-
liminary birth data have been published in other reports (6,7).
Results
A 23% decline occurred in neural tube defects (spina bifida
and anencephaly combined) in 2001, compared with 1996;
births in 1996 were conceived before folic acid fortification
was authorized. The prevalence of spina bifida reported on
birth certificates declined from 24.88 (95% CI = 23.25–26.52)
per 100,000 live births in 1991 to 20.09 (95% CI = 18.63–
21.54) in 2001 (Table, Figure). The birth prevalences for 1999,
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2000, and 2001 were significantly lower than in 1996 (pre-
fortification). The 2001 prevalence was 24% lower than the
prevalence in 1996; after a significant increase in the preva-
lence during 1992–1995, a significant decline occurred dur-
ing 1995–1998. The birth prevalence of spina bifida was stable
during 1999–2001. The prevalence of anencephaly reported
on birth certificates declined from 18.38 (95% CI = 16.97–
19.78) per 100,000 live births in 1991 to 9.40 (95% CI =
8.40–10.39) in 2001. After a decline in the early part of the
decade, the anencephaly prevalence was stable during the mid-
1990s. The prevalence of anencephaly in 2001 was 21% lower
than in 1996. The birth prevalence did not change signifi-
cantly during 1998–2001, the period of optional and manda-
tory folic acid fortification.
Discussion
Spina bifida and anencephaly are serious birth defects that
occur when the neural tube fails to close properly during fetal
development. Anencephaly is a lethal defect, and spina bifida
results in serious long-term morbidity and disability. Before
folic acid fortification, approximately 4,000 pregnancies
resulted in 2,500–3,000 births in the United States each year
affected by one of these two neural tube defects (1,8)
U.S. birth certificate data in this report demonstrate a 24%
decline in spina bifida in 2001 births (based on preliminary
data) compared with the occurrence of spina bifida in 1996
(before folic acid fortification). A decline of 21% in anen-
cephaly was observed during the same period. This decline is
similar to those observed by using the first 5 quarters
postfortification, which was previously published (5).
Although prevalence for birth defects (including spina bifida
and anencephaly) as reported from birth certificate data has
been underreported, the collection over time is considered to
be stable (5,9). Further support of the findings from birth
certificate data has come from population-based surveillance
systems. Data from 24 birth defect surveillance systems indi-
cated a 31% decline in spina bifida and a 16% decline in
anencephaly when comparing the postfolic acid fortification
years (October 1998–December 1999) with the pre-fortifica-
tion years (January 1995–December 1996) (10).
* Excludes data for Maryland, New Mexico, and New York, which did not
require reporting for spina bifida and anencephaly for certain years.† 95% confidence interval.§ Data for 2001 are preliminary.
Source: National Vital Statistics System, National Center for Health
Statistics, CDC.
FIGURE. Spina bifida and anencephaly prevalence — United
States, 1991–2001*
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TABLE. Number of live births and prevalence* for spina bifida and anencephaly — United States, 1991–2001†
                                             Spina bifida                                             Anencephaly
Year No. cases Prevalence (95% CI§) No. cases Prevalence (95% CI) Total no. live births
1991 887 24.88 (23.25–26.52) 655 18.38 (16.97–19.78) 3,564,453
1992 816 22.84 (21.27–24.41) 457 12.79 (11.62–13.96) 3,572,890
1993 896 25.15 (23.50–26.80) 481 13.50 (12.29–14.71) 3,562,723
1994 900 25.51 (23.85–27.18) 387 10.97 (9.88–12.06) 3,527,482
1995 975 27.98 (26.22–29.74) 408 11.71 (10.57–12.84) 3,484,539
1996 917 26.36 (24.65–28.07) 416 11.96 (10.81–13.11) 3,478,723
1997 857 24.70 (23.05–26.35) 434 12.51 (11.33–13.69) 3,469,667
1998 790 22.45 (20.88–24.01) 349 9.92 (8.88–10.96) 3,519,240
1999 732 20.72 (19.22–22.22) 382 10.81 (9.73–11.89) 3,533,565
2000 759 20.85 (19.37–22.33) 376 10.33 (9.28–11.37) 3,640,376
2001¶ 733 20.09 (18.63–21.54) 343 9.40 (8.40–10.39) 3,649,061
* Per 100,000 live births.† Excludes data for Maryland, New Mexico, and New York, which did not require reporting for spina bifida and anencephaly for certain years.§ Confidence interval.¶ Data for 2001 are preliminary.
Source: National Vital Statistics System, National Center for Health Statistics, CDC.
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Nine of these birth defect surveillance systems ascertain
defects that are prenatally diagnosed and terminated, allow-
ing them to capture additional defects. Larger declines after
folic acid fortification were observed for both spina bifida and
anencephaly when analysis was limited to these nine surveil-
lance systems with enhanced ascertainment (10).
Maryland and New York were excluded in this report to
provide consistent trend data, because they only began report-
ing both spina bifida and anencephaly in 1996. The inclusion
of data from these two states does not have a significant effect
on the overall prevalence for spina bifida or anencephaly, nor
does it change the direction or pattern of change in the trend.
New Mexico data are not available because the state does not
require reporting of these defects on birth certificates.
The declines observed in both birth certificate data and birth
defects surveillance system data are less than the decline of
>50% that was predicted on the basis of certain observational
studies (1). Possible explanations for this difference include
1) the majority of folate-preventable neural tube defects in the
United States might have been eliminated before fortification
or 2) subpopulations of U.S. women might have not received
adequate folic acid from either folic acid fortification or folic
acid supplementation. Alternatively, the findings from the
observational studies might not be applicable to
populationwide interventions (e.g., folic acid fortification),
possibly because of biases or uncontrolled confounding that
might have been present in the observational studies.
The 23% decline in neural tube defects (spina bifida and
anencephaly combined) indicated by birth certificate data
translates to approximately 920 additional babies without
neural tube defects being born in the United States each year.
Although this decline represents a lower reduction than those
predicted on the basis of earlier studies, by September 2002,
neural tube defects will have been prevented in nearly 4,000
U.S. children after folic acid fortification. Attaining and sus-
taining these substantial declines in neural tube defects is an
important public health achievement.
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Summary
Previous studies have documented a decline in neural tube defects (NTDs) in the United States after the addition of folic acid
to enriched grain products and other folic acid initiatives. The decrease generally has been greater for spina bifida than for other
NTDs. However, the extent to which the decline varies by maternal sociodemographic characteristics has not been examined. In
this study, data from the North Carolina Birth Defects Monitoring Program, a statewide, population-based birth defect surveil-
lance program, were used to assess the impact that folic acid public health initiatives have had on spina bifida rates among various
sociodemographic subpopulations in North Carolina. This report covers data from 1995 through 1999. The overall prevalence of
spina bifida decreased by 27.2% during 1995–1996 and 1998–1999 (p = 0.014). The magnitude of the decline varied consid-
erably by sociodemographic characteristics of the mother. The decline was greatest among mothers who were aged >30 years
(prevalence ratio [PR] = 0.53), who had more than a high school education (PR = 0.57), whose prenatal care was not paid by
Medicaid (PR = 0.67), and who were non-Hispanic white (PR = 0.72). Geographically, the decrease in the western and Pied-
mont regions of the state was almost threefold that occurring in the eastern region. The decline in spina bifida after fortification
varied considerably by sociodemographic subpopulations. More effort is needed to target folic acid education programs at disadvan-
taged populations.
Introduction
Previous studies have demonstrated a decline in the birth
prevalence of spina bifida after the addition of folic acid to
enriched grain products and the initiation of folic acid educa-
tion programs during the 1990s. An analysis of birth certifi-
cate data in the United States found that the rate of spina
bifida declined 16% during 1991–2000 (1). A subsequent
study using U.S. birth certificate data documented a 23%
decline in spina bifida after fortification (2), and a recent analy-
sis of data from 24 state birth defects surveillance programs
also demonstrated a decline in spina bifida prevalence since
the mid-1990s (3). Although the findings of these studies dem-
onstrate that spina bifida has declined in the years following
fortification, the extent to which this decline varies by
sociodemographic characteristics has not been assessed. This
report describes the association between maternal
sociodemographic factors and recent trends in spina bifida in
North Carolina. This information can be helpful for assessing
the effects that folic acid initiatives have had on various seg-
ments of the population and for identifying subgroups for
which targeted educational activities are most needed.
Methods
Case Definition and Ascertainment
Cases of spina bifida were identified from the North Caro-
lina Birth Defects Monitoring Program (NCBDMP). The
NCBDMP is a statewide, population-based surveillance sys-
tem that collects information on congenital malformations
diagnosed within the first year of life among North Carolina
resident liveborn infants and among stillborn infants aged >20
weeks’ gestation. The surveillance system covers a birth popu-
lation of >110,000 deliveries annually. Beginning with births
occurring in 1995, the NCBDMP initiated an enhanced sys-
tem for ascertaining infants with neural tube defects (NTDs).
Trained case abstractors conducted routine visits at the state’s
12 tertiary hospitals to review medical records and abstract
information about infants suspected of having NTDs or other
birth defects. Suspected cases were identified through review-
ing hospital disease indexes and through genetics and prenatal
diagnosis logs in selected hospitals. Data sources used to iden-
tify cases at non-tertiary hospitals include hospital discharge
data, vital statistics, and Medicaid paid claims files. All sus-
pected NTD cases were confirmed through chart review.
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FIGURE. Prevalence (per 10,000 live births) of spina bifida by
year — North Carolina, 1995–1999
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Cases of spina bifida were defined according to International
Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) codes 741.00–741.93 (4) and included those
affecting all resident liveborn infants and stillborn infants aged
>20 weeks’ gestation delivered during 1995–1999. A total of
299 spina bifida cases were identified during the 5-year study
period, resulting in 279 live births and 20 fetal deaths.
Data Analysis
Cases were matched with the North Carolina composite
matched birth files for 1995–1999. This database contains
information extracted from vital statistics files (matched birth
and infant death certificates), Medicaid paid claims, and other
health services-related data for all North Carolina resident
births. The prevalence of spina bifida (number of cases per
10,000 births) for each year was calculated overall and for the
following maternal characteristics: age, race, education, Med-
icaid status (as defined by whether the delivery was paid for
by Medicaid), and geographic area of residence.
Poisson regression was used to examine the overall trend in
the spina bifida prevalence during 1995–1999. This method
is appropriate for modeling disease incidence data in which
the event (numerator) is relatively rare in proportion to the
total population at risk (5). A Poisson log-linear model was
fitted to the data by using SAS PROC GENMOD (6), mod-
eling the change in rates as a function of year. To assess whether
the change in prevalence varied according to maternal charac-
teristics, the prevalence for the most recent 2-year period
(1998–1999) was compared with that of the earliest period
(1995–1996) for each of the previously described
sociodemographic variables. Prevalence ratios (PR) and 95%
confidence intervals (CI) were computed to compare the two
time periods.
Results
The number of spina bifida cases in North Carolina
declined from 63 in 1995 to 48 in 1999, despite the 12%
increase in the total number of live births in the state during
this period. During 1995–1999, the overall prevalence of spina
bifida declined by 32% (p = 0.015, based on Poisson regres-
sion), from 6.20/10,000 live births in 1995 to 4.22/10,000 in
1999 (Figure).
Comparing the earliest and most recent 2-year periods
(1995–1996 and 1998–1999), the overall spina bifida preva-
lence declined by 27.2% (PR = 0.73, 95% CI = 0.56–0.94).
However, the magnitude of the decrease differed substantially
according to maternal characteristics (Table). The greatest
declines were seen among mothers in the older age groups,
especially women aged >30 years, in which the prevalence de-
creased by 47.0% (PR = 0.53, 95% CI = 0.33–0.84). In con-
trast, among women aged <25 years, the prevalence remained
virtually unchanged (PR = 0.99, 95% CI = 0.67–1.45). The
spina bifida prevalence for women with more than a high
school education declined by 43.2% (PR = 0.57), which was
about 2.5 times the amount of decline observed among women
with a high school education or less. Among women whose
prenatal care was not paid by Medicaid, the prevalence
declined by about one third (PR = 0.67), compared with an
18.5% decrease for women receiving Medicaid. Differences
in the decrease in spina bifida by race were less marked,
although the decline among white non-Hispanic mothers was
slightly greater compared with the decline among minority
women (PR = 0.72 and 0.76, respectively). Geographic dif-
ferences also were observed in the decline of spina bifida;
decreases in western North Carolina and in the Piedmont re-
gion were nearly threefold those experienced in the East.
Discussion
The decrease in the rate of spina bifida since the mid-1990s
is consistent with previous reports that have demonstrated simi-
lar declines in the United States (1–3). However, this study
reveals that the reduction in spina bifida in North Carolina
was not uniform across the population, but varied by geo-
graphic region as well as by maternal sociodemographic char-
acteristics. The decline was generally greater among women
who tend to be of higher socioeconomic status (i.e., those who
are older, have higher education, and are not receiving Medic-
aid. The decrease was also considerably greater in the western
and Piedmont regions of the state compared with the eastern
coastal plain, a pattern that reflects the sociodemographic
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differences among these regions. In addition, western North
Carolina was the first area of the state to initiate a well-
coordinated and intensive folic acid education program; this
effort may have contributed to the dramatic decline observed
in that region.
Much of the recent decline in NTDs in the United States
has been attributed to the mandatory fortification program
rather than to increased intake of multivitamins. Data from
the March of Dimes/Gallup surveys indicate that the percent-
age of women aged 18–44 years who take daily multivitamins
has increased only slightly since 1995 (7). In addition, pre-
liminary data from the National Health and Nutrition
Examination Survey (NHANES) IV indicate that supplement
use among women of childbearing age was similar to that
reported among women participating in the NHANES III
survey; yet, blood folate levels increased significantly during
the 5 years between the two surveys (8). As indicated by the
present study, however, the fortification program in the United
States may not have benefited all segments of the population
equally. One explanation is that sociodemographic differences
in food consumption patterns and multivitamin intake may
be mediating the effect that fortification is having in various
subpopulations.
Some nationally representative studies have documented
differences in consumption patterns of enriched grain prod-
ucts by sociodemographic characteristics. For example, per-
sons with higher income, those with more education, and
non-Hispanic whites tend to consume more cereals (9–12).
These differences in cereal consumption are noteworthy
because of the now widespread availability of ready-to-eat
breakfast cereals that are fortified at 100% of the recommended
daily value. Furthermore, total folate intakes are higher among
non-Hispanic white and black women in the middle and
upper socioeconomic classes compared with the lowest
(US Department of Agriculture. Continuing Survey of Food
Intake by Individuals, 1994–1996, unpublished data).
Although more studies are needed to determine whether these
food consumption patterns persist in the postfortification era,
the data that are available correlate with the sociodemographic
trends in spina bifida reported in this study.
Like dietary patterns, multivitamin use also differs by
sociodemographic characteristics (13–15). Several studies dem-
onstrate that older, higher income, non-Medicaid, and better
educated women are more likely to be taking supplements.
The greatest declines in spina bifida have occurred among
infants born to women of these same sociodemographic groups.
Folic acid fortification might be having a greater effect in
reducing NTD risk among those women whose nutritional
status is already near an optimal level, e.g., women who are
more likely to consume ready-to-eat cereals, to take multivita-
mins on an occasional basis, and to maintain a more well bal-
anced diet. The current fortification level has been estimated
to increase the average woman’s consumption of folic acid by
about 100 µg per day (16). Although this amount is only about
one fourth of the total intake recommended by CDC for birth
defects prevention, it may be sufficient for women whose
baseline folates were already at or above the prefortification
median levels. For these women, fortification may have
TABLE. Prevalence of spina bifida (per 10,000 live births) by selected maternal characteristics — North Carolina, 1995–1996 and
1998–1999
                                1995–1996                                 1998–1999
Prevalence Prevalence Prevalence
Characteristic No. (per 10,000 births) No. (per 10,000 births) ratio 95% CI*
Mother’s age
<25 years 52 5.91 54 5.83 0.99 0.67–1.45
25–29 years 34 6.11 24 3.83 0.63 0.37–1.06
>30 years 47 7.55 28 3.99 0.53 0.33–0.84
Mother’s education
High school or less 85 7.43 75 6.18 0.83 0.61–1.13
Beyond high school 42 4.61 27 2.62 0.57 0.34–0.92
Mother’s race
White/non-Hispanic 95 7.00 72 5.04 0.72 0.53–0.98
Other 38 5.41 34 4.12 0.76 0.48–1.21
Mother’s Medicaid status
Medicaid 70 7.18 60 5.86 0.82 0.58–1.15
Non-Medicaid 53 4.88 40 3.25 0.67 0.44–1.00
Geographic region
Western 30 8.67 21 5.63 0.65 0.37–1.13
Piedmont 62 6.03 47 4.05 0.67 0.46–0.98
Coastal Plain 41 5.99 38 5.28 0.88 0.57–1.37
Total 133 6.46 106 4.70 0.73 0.56–0.94
* Confidence interval.
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provided sufficient additional folic acid in their diets to raise
their folate levels to the optimal threshold needed to prevent
birth defects. Such women tend to be from more affluent
sociodemographic populations. In contrast, among women
from more disadvantaged groups who tend to be in poorer
nutritional status and are less likely to take any multivitamins,
the current fortification level might be considerably less than
the amount needed for full birth defects prevention.
The possibility that the recent decline in spina bifida is only
part of a secular trend in the prevalence of NTDs cannot be
ruled out. Throughout much of the world, the rate of NTDs
has been declining during the past several decades (17), and
to some extent, the decrease seen in recent years can be viewed
as a continuation of that trend. In this context, gauging the
extent to which folic acid interventions may have contributed
to the recent decline is difficult. Nevertheless, the increase in
blood folate levels in the United States, combined with evi-
dence of concomitant decrease in NTDs from multiple stud-
ies, supports the view that folic acid initiatives are contributing
to the prevention of NTDs.
The extent to which the recent decline in spina bifida and
other NTDs may be attributed to mandatory fortification,
increased multivitamin intake, or increased availability of fully
fortified, ready-to-eat cereals cannot be assessed with the data
available. Most likely, all these factors combined have led to
the dramatic improvements seen in recent years and help
explain why certain segments of the population have benefited
more than others.
Additional studies using data from population-based birth
defect surveillance programs are needed to confirm the results
of this study. The present findings indicate that substantial
potential still exists for further reductions in spina bifida,
particularly among minorities and women of lower socioeco-
nomic status. With the effects of the fortification program
probably having already been realized, sustaining the decline
will require more aggressive efforts to encourage minority
women of childbearing age, as well as those from lower socio-
economic groups, to take daily multivitamins containing 400
µg of folic acid in addition to eating a well-balanced, folate-
rich diet.
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Summary
The use of folic acid is a critical component in preventing birth defects. Health-care providers should take advantage of all
health-care visits to counsel not only women at high risk (i.e., those with a history of having an infant with a neural tube defect
[NTD]) but all women regarding the importance of folic acid use. A study conducted in Texas confirmed that white and Hispanic
mothers were equally likely to recall receiving postpartum advice to use folic acid; however, Hispanic women were much less likely
to use folic acid, compared with white women. This report covers data from May 2000 through November 2001. A study was
conducted in Texas to determine whether women at high risk recall and follow recommendations to use folic acid. The study
included 195 women at high risk and 223 control mothers who gave birth to infants without birth defects. These women
participated in a telephone interview for a population-based case-control study of NTDs. Approximately 56.4% (110 of 195) of
mothers who had infants affected by an NTD recalled receiving postpartum advice to use folic acid, compared with 25.6% (57 of
223) of control mothers (p < 0.01). Among nonpregnant case mothers, 54 (32.7%) of 165 reported regular use of supplements
containing folic acid, and 53 (25.2%) of 210 nonpregnant control mothers reported this behavior (p = 0.11). Among case
mothers, use of folic acid was significantly higher for whites (64.7%) versus Hispanics (16.5%) (p < 0.001); for women with
some college education (57.1%) versus no college education (20.2%; p < 0.001); for women who were trying to get pregnant
(66.7%) versus those using birth control (38.3%) or reporting using no contraceptive method (18.8%) (p = 0.001); and for
women who reported receiving advice to use folic acid (40.9%) versus those who did not (22.2%; p = 0.01). Findings from this
study support the need to implement NTD recurrence prevention activities in Texas. Data also identify a need for educational
strategies in Texas that target Hispanic women at high risk, especially those who primarily speak Spanish. Further efforts should be
made to determine why Hispanic women have low rates of folic acid use (e.g., the cost of vitamins and language and cultural
barriers). On the basis of a review of research and current practice, recommendations developed by the Public Health Service
include 1) women at risk for a recurrent NTD-affected pregnancy should take 0.4 mg of folic acid per day; and 2) if a woman at
high risk is planning a pregnancy, she should consult her physician regarding taking the higher dose of 4.0 mg per day.
Background
For women who previously have had a neural tube defect
(NTD)-affected infant, the risk for having another is
1%–3%, or 10–30 times the risk among the general popula-
tion (1,2). From 1993 through 1999, a CDC-funded, popu-
lation-based intervention study of these women at high risk
was conducted among a primarily Hispanic population resid-
ing in Texas counties bordering Mexico (3). The success of
this intervention indicated that NTD recurrence prevention
activities should possibly be expanded in Texas. To determine
the need for statewide NTD recurrence prevention, this
statewide study was conducted to assess awareness and
supplementation practices among women who recently
delivered NTD-affected infants.
Methods
This study is an add-on component to the National Birth
Defects Prevention Study, a multistate, case-control study of
risk factors for 35 major birth defects sponsored by CDC (4).
Eight states, including Texas, participated in the study, using
a standardized, 60-minute, computer-assisted telephone
interview and informed consent. In Texas, mothers who par-
ticipated in the national interview and who had children with
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TABLE 1. Proportion of mothers who recall having received postpartum advice to use folic acid — Texas, 2000–2001
Mothers of infants with NTD* Control mothers†
Category Yes/Total (%) P value Yes/Total (%) P value
Spina bifida 61/110 (55.5) 0.76 — — —
Anencephaly 49/85 (57.6) — — — —
Race/Language
White/English 42/67 (62.7) 0.63 24/82 (29.3) 0.78
Hispanic/English 29/53 (54.7) — 16/66 (24.2) —
Hispanic/Spanish 29/56 (51.8) — 11/46 (23.9) —
Other/English 10/19 (52.6) — 6/29 (20.7) —
Education
<High school graduate 70/125 (56.0) 0.88 29/130 (22.3) 0.19
Some college or college graduate 40/70 (57.1) — 28/93 (30.1) —
Age group (yrs)
<18 8/16 (50.0) 0.004 2/13 (15.4) 0.62
18–29 83/129 (64.3) — 38/149 (25.5) —
>30 18/49 (36.7) — 17/60 (28.3) —
Contraceptive status
Currently pregnant 17/30 (56.7) 0.94 3/13 (23.1) 0.87
Trying to get pregnant 9/15 (60.0) — 1/7 (14.3) —
Using birth control 47/81 (58.0) — 23/83 (27.7) —
Other 37/69 (53.6) — 30/120 (25.0) —
Outcome
Live birth 62/120 (51.7) 0.12 57/223 (25.6) §
Fetal death 13/24 (54.2) — 0/0 (00.0) —
Induced abortion 35/51 (68.6) — 0/0 (00.0) —
Total 110/195 (56.4) — 57/223 (25.6) —
* Neural tube defects.†No birth defects occurred among controls.§Controls are comprised of live births only.
NTDs (i.e., spina bifida and anencephaly) were invited to
participate in an additional 20-minute interview (Texas Inter-
view for Prevention of Central Nervous System Birth Defects
[TIP-CNS]). The current study includes 195 mothers of
infants with NTDs and 223 control mothers who participated
in both of these interviews. All data regarding folic acid aware-
ness and use of folic acid at the time of the interview derived
from the TIP-CNS interview.
Telephone interviews for the study participants were con-
ducted during May 2000–November 2001. Eligible women
were contacted by telephone and invited to participate in the
interview, which was administered in English or Spanish. The
median time between delivery or pregnancy termination and
the interview was 15 months (range: 3.4 months–34.4 months)
for case mothers and 14.1 months (range: 1.4 months–32.9
months) for control mothers. Estimated participation rates
were 57% (195 of 342) for case mothers and 51% (223 of
437) for control mothers.
Cases were ascertained by the population-based Texas Birth
Defects Monitoring Program, an active surveillance system
for all birth defects diagnosed among elective pregnancy ter-
minations, fetal deaths, live births, and infants (aged <1 year)
(5). Cases were identified by an active search of medical records
in all hospitals in Texas. Chromosomal abnormalities and syn-
dromes are ascertained by the monitoring program but were
not included in this study. Controls were live infants without
malformations who were randomly selected from the same
Texas hospitals from which the cases were ascertained, in pro-
portion to the live birth proportion contributed by that hos-
pital during the previous year.
Women who stated that they took folic acid or multivita-
mins the majority of days or every day were considered to be
regular users of folic acid supplements. Women who responded
that they took folic acid occasionally or never were classified
as nonusers.
Results
Mothers of infants affected by NTDs were much more likely
to remember receiving postpartum advice to use folic acid from
a physician or health-care worker, (n = 195; 56.4%), compared
with control mothers, (n = 223; 25.6%; p < 0.01) (Table 1).
Recall of advice regarding folic acid among case mothers did
not differ by type of defect, race/ethnicity, education, preg-
nancy/contraceptive status, or outcome of pregnancy. Demo-
graphic patterns (e.g., race/ethnicity and education) for recall
among control mothers were similar to those for case mothers.
To determine the proportion of women who were comply-
ing with the recommendation to use folic acid before they
become pregnant, women who were pregnant at the time of
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TABLE 2. Proportion of nonpregnant mothers who reported taking folic acid regularly — Texas, 2000–2001
Mothers of infants with NTD* Control mothers†
Category Yes/Total (%) P value Yes/Total (%) P value
Spina bifida 29/99 (29.3) 0.25 — — —
Anencephaly 25/66 (37.9) — — — —
Race/Language
White/English 33/51 (64.7) <0.001 33/77 (42.9) <0.001
Hispanic/English 9/45 (20.0) — 11/63 (17.5) —
Hispanic/Spanish 7/52 (13.5) — 4/44 ( 9.1) —
Other/English 5/17 (29.4) — 5/26 (19.2) —
Education
<High school graduate 22/109 (20.2) <0.001 20/124 (16.1) <0.001
Some college or college graduate 32/56 (57.1) — 33/86 (38.4) —
Age group (yrs)
<18 1/12 (8.3) 0.13 1/12 (8.3) 0.25
18–29 40/110 (36.4) — 35/142 (24.6) —
>30 13/43 (30.2) — 17/55 (30.9) —
Contraceptive status
Trying to get pregnant 10/15 (66.7) 0.001 2/7 (28.6) 0.98
Using birth control 31/81 (38.3) — 21/83 (25.3) —
Other 13/69 (18.8) — 30/120 (25.0) —
Outcome
Live birth 31/106 (29.2) 0.42 53/210 (25.5) §
Fetal death 8/19 (42.1) — 0/0 (00.0) —
Induced abortion 15/40 (37.5) — 0/0 (00.0) —
Advised to use folic acid
Yes 38/93 (40.9) 0.01 20/54 (37.0) 0.02
No 16/72 (22.2) — 33/156 (21.2) —
Total 54/165 (32.7) — 53/210 (25.2) —
* Neural tube defects.† No birth defects occurred among controls.§ Controls are comprised of live births only.
the interview were excluded from the analyses (Table 2). Among
nonpregnant case mothers, 54 (32.7%) of 165 reported regu-
lar use of multivitamins or folic acid at the time of the inter-
view, compared with 53 (25.2%) of 210 control mothers.
Among nonpregnant case mothers, regular use of folic acid or
multivitamins varied substantially across ethnic groups:
33 (64.7%) of 51 white women, 9 (20.0%) of 45 English-
speaking Hispanic women, and 7 (13.5%) of 52 Spanish-
speaking Hispanic women (p < 0.001) (Table 2). A similar
difference was observed among nonpregnant control women,
(p < 0.001) (Table 2). Among nonpregnant case and control
mothers, those with some college education were more than
twice as likely to use folic acid regularly than those with no
college education (p < 0.001 for case and control mothers)
(Table 2). In addition, both case and control mothers who
reported having received postpartum advice to use folic acid
were nearly twice as likely to be taking supplemental folic acid
at the time of the interview, compared with mothers who did
not recall such advice (p = 0.01 for case mothers; p = 0.02 for
control mothers).
Nonpregnant case mothers who reported that they were try-
ing to get pregnant were much more likely to report regular
use of folic acid: 10 (66.7%) of 15 were regular users, com-
pared with 31 (38.3%) of 81 women using birth control, and
13 (18.8%) of 69 women who did not use birth control
(p = 0.001) (Table 2). This last category includes women who
were sexually inactive and women who were sexually active
but elected not to use birth control. The interview questions
did not distinguish between these two categories. In contrast,
among control mothers, the corresponding rates were not sig-
nificantly different; rates were 28.6%, 25.3%, and 25.0%,
respectively (p = 0.98).
Recall of receiving advice to use folic acid did not vary by
time between delivery and interview (categories examined:
1–6 months, 7–12 months, 13–18 months, and 19–35
months). Therefore, time from interview is not likely to be a
bias in our results. No appreciable change occurred in these
findings after adjustment for maternal age, ethnic group, edu-
cational level, contraceptive status, pregnancy outcome, and case-
control status.
Discussion
Of study subjects who had a previous NTD-affected preg-
nancy, 43% did not recall receiving advice regarding taking
folic acid supplements of any type, and only approximately
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one third (32.7%) of nonpregnant subjects were using folic
acid supplements regularly. Given the 1%–3% level of risk for
NTD recurrence among this population, the percentage of
women receiving this counseling must be improved. Other
studies based on different methods have reported similar find-
ings (6–9).
This survey has certain limitations. The participation rates
in this study were low, but they were similar to those of other
recently conducted case-control studies (10). Women of lower
educational status might be underrepresented, because they
move more often and are less likely to have a telephone. They
also have lower rates of awareness and use of folic acid (11).
Therefore, rates of awareness and use of folic acid among all
women in Texas with NTD-affected pregnancies might be
lower than the rates in this report. In addition, differences
across ethnic groups might be larger than the differences in
this report.
Health-care providers should take advantage of all health-
care visits to counsel not only women at high risk but all women
regarding the importance of folic acid use. Although white
mothers and Hispanic mothers were equally likely to recall
receiving postpartum advice to use folic acid, Hispanic women
were much less likely to use folic acid, compared with white
women. Therefore, further efforts should be made to explore
the reasons that Hispanic women have such low rates of folic
acid use, including the cost of vitamins and language and
cultural barriers.
A substantial number of unintended pregnancies occur
among women using hormonal contraceptives (12). There-
fore, women should be advised to take folic acid every day
regardless of whether they use contraceptives. Women who
were not trying to become pregnant and were not using con-
traception were the least likely to use folic acid. Reaching these
women is vital, because they have a high risk of becoming
pregnant and because, on average, their economic status is
lower (12), placing them at a higher risk for having an infant
with an NTD (13).
The low rates of awareness and use of folic acid among
women at high risk and the complex decision-making pro-
cesses involved in reproductive health support the need for
programs to identify women at high risk and to counsel them
regarding folic acid use. Such programs use educational
approaches specifically tailored for women at high risk and
are a key adjunct to counseling by physicians and other health-
care providers. These findings are important to consider as
Texas develops its statewide NTD recurrence prevention
strategy.
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